[
  {
    "ts": null,
    "headline": "Bloom Energy, Lumentum, and Other Hot Stocks Set up for Earnings Beats",
    "summary": "Which companies are most likely to beat Wall Street profit forecasts?  Investors can get a big clue by looking at recent changes to a key metric: the price-to-earnings ratios.  When it comes to picking stocks, conventional wisdom holds that low price-to-earnings ratios are an advantage.",
    "url": "https://finnhub.io/api/news?id=b97baf06f1ece77361927c2cb73501980bb4553e1b70ab43f67c576b654ce21f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769328000,
      "headline": "Bloom Energy, Lumentum, and Other Hot Stocks Set up for Earnings Beats",
      "id": 138251834,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Which companies are most likely to beat Wall Street profit forecasts?  Investors can get a big clue by looking at recent changes to a key metric: the price-to-earnings ratios.  When it comes to picking stocks, conventional wisdom holds that low price-to-earnings ratios are an advantage.",
      "url": "https://finnhub.io/api/news?id=b97baf06f1ece77361927c2cb73501980bb4553e1b70ab43f67c576b654ce21f"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Vs. Eli Lilly: The Tide May Be Turning For The Underdog",
    "summary": "Novo Nordisk has global metabolic leadership, an oral GLP-1 program, and a stock price below $50 after a retail-driven selloff. Find out why NVO stock is a buy.",
    "url": "https://finnhub.io/api/news?id=2719bc29e4509cc0bc122a7634bed831f8a277b2ddcc9025f30018f9fe1e6ac1",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769322383,
      "headline": "Novo Nordisk Vs. Eli Lilly: The Tide May Be Turning For The Underdog",
      "id": 138252356,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1400270760/image_1400270760.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Novo Nordisk has global metabolic leadership, an oral GLP-1 program, and a stock price below $50 after a retail-driven selloff. Find out why NVO stock is a buy.",
      "url": "https://finnhub.io/api/news?id=2719bc29e4509cc0bc122a7634bed831f8a277b2ddcc9025f30018f9fe1e6ac1"
    }
  }
]